Here is What Analysts Are Saying About McKesson Corporation (MCK)

McKesson Corporation (NYSE:MCK) is one of top cheap stocks with Strong Buy ratings on Wall Street. Citi cut the price target on McKesson Corporation (NYSE:MCK) to $945 from $975 on May 14 and reiterated a Buy rating on the shares. The company also received a rating update from BofA on May 8, with the firm cutting the price target on the stock to $900 from $1,000 while maintaining a Buy rating on the shares. The firm stated that while the company reported “a mixed quarter”, its FY27 guidance and long-range plan reiteration were “clear positives”. It noted that the firm’s lower target reflects peer multiple contraction.

UBS Says McKesson’s (MCK) FY27 Outlook Looks “Good Enough” After Q4

In its financial results for fiscal Q4 and fiscal year ended March 31, 2026, McKesson Corporation (NYSE:MCK) reported consolidated revenues of $96.3 billion for the quarter, up 6%, and $403.4 billion for the full year, up 12%. Earnings per diluted share for the quarter increased $3 to $13.71, while the same for the full year rose $12.66 to $38.38.

McKesson Corporation (NYSE:MCK) provides healthcare services. The company’s operations are divided into the following segments: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions (RxTS), and Medical-Surgical Solutions.

While we acknowledge the risk and potential of MCK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MCK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1